A case of metastatic castration-resistant prostate cancer by abiraterone treatment / 中南大学学报(医学版)
Journal of Central South University(Medical Sciences)
;
(12): 688-692, 2015.
Article
in Chinese
| WPRIM
| ID: wpr-815286
ABSTRACT
We reviewed and analyzed the clinical data for a patient with metastatic castration-resistant prostate cancer (mCRPC) from September, 2009 to December, 2014. After the treatment with abiraterone, patient's performance status improved, pain relieved, total prostate specific antigen (tPSA) and free prostate specific antigen (fPSA) markedly decreased. tPSA or fPSA fluctuated between
30 and 50 ng/mL or between 10 and 20 ng/mL. MRI showed the left peripheral zone reduced. MRI and bone single photon emission computed tomography (SPECT) scan showed no new metastasis. These results indicated that application of abiraterone for patient with mCRPC not only decreased prostate specific antigen (PSA) levels and tumor volume, but also blocked bone metastasis progression and enhanced pain relief.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Blood
/
Bone Neoplasms
/
Prostate-Specific Antigen
/
Disease Progression
/
Therapeutic Uses
/
Drug Therapy
/
Prostatic Neoplasms, Castration-Resistant
/
Androstenes
Limits:
Humans
/
Male
Language:
Chinese
Journal:
Journal of Central South University(Medical Sciences)
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS